As 2025 draws to a close, Syngene International is no longer the newcomer in Baltimore’s fast-growing biomanufacturing landscape. With the acquisition of its Baltimore facility earlier this year—its first U.S. site and a milestone in Syngene’s expansion into the United States—the company has spent the past nine months building momentum and integrating deeply into the region’s collaborative ecosystem. Today, Syngene is finishing the year with a 35-person team, a strong talent pipeline, and clear confidence in Baltimore as its U.S. biomanufacturing home.
Building a Team, and a Home, in Baltimore
Syngene’s entrance into Maryland marked a significant strategic shift: establishing a U.S. operational base to support global clients more efficiently. What has followed in 2025 is impressive—consistent hiring, community involvement, and the foundational work needed to bring new biologics manufacturing capacity online in 2026.
The company reports that Baltimore’s talent market has exceeded expectations, noting both the technical caliber and mission-driven mindset of the workforce. New hires span manufacturing, quality, engineering, and operations—roles essential for validating systems and preparing for production readiness.
Vice President and Site Head, Dave Kohler had encouraging words to share about his experience leading the facility launch this year.
“Baltimore has given us the ideal foundation to grow. The depth of talent, the strength of the local biotech ecosystem, and the support from workforce development partners have all contributed to a remarkable start,” Kohler shared.
“I’m incredibly grateful for the team we’ve built so far—their commitment and expertise are driving this site forward every day. We’re excited to be investing here and optimistic about what’s ahead as we move toward manufacturing in 2026.”
A Year of Listening, Learning, and Showcasing Baltimore to the World
One of the standout themes of 2025 has been how actively Syngene has embraced—and elevated—Baltimore’s growing biomanufacturing identity.
Throughout the year, Syngene welcomed global colleagues from India, Europe, and across the U.S. for site tours and strategy discussions. Visitors consistently highlighted Baltimore’s welcoming culture, strong industry support network, and emerging leadership in biologics manufacturing.
A major highlight was the success of Syngene’s first-ever Consultant Day, where the company hosted a curated group of CMC consultants from across the industry. Participants enjoyed a welcome reception at Camden Yards for an Orioles Game, which preceded an interactive day discussing CDMO market dynamics, emerging biomanufacturing trends, and evolving client expectations, followed by a tour of the new Baltimore facility. The event not only provided valuable market insight to Syngene but also showcased Baltimore’s growing role in shaping global biomanufacturing conversations.
These interactions have helped amplify Baltimore’s visibility on the world stage—positioning the region as a serious contender for advanced manufacturing investment. Just recently Korean Stem Cell Manufacturing firm, Nature Cell, also announced plans for a new state of the art facility and 500 new jobs in Baltimore.
Plugging into Maryland’s Innovation Engine
Syngene has also become an active partner within Maryland’s innovation ecosystem. In 2025, the company engaged in several regional initiatives, including the Tech Hubs biomanufacturing grant led by GBC, aimed at expanding domestic production capacity and strengthening U.S. supply chain resilience.
This involvement underscores a larger theme: Syngene isn’t simply operating in Baltimore; it is helping co-create the infrastructure, partnerships, and talent systems that will shape the region’s next generation of biomanufacturing capability.
Eyes on 2026: Poised for Production and Continued Growth
With building acquisition completed earlier this year and the core team now in place, Syngene enters 2026 preparing for a major transition—from site establishment to active production.
Key expectations for the year ahead include:
- Operational readiness for initial manufacturing activities
- Continued expansion of the Baltimore-based workforce
- Process and equipment validation throughout the new facility
- Deeper collaboration across the region’s workforce, supplier, and innovation partners
- Increased engagement with global clients as the Baltimore site becomes fully tour- and project-ready.
If 2025 was about laying the groundwork, 2026 will be about turning on the engines.
A Fast-Forming Pillar of the Baltimore Biotech Community
In the span of a year—and with the acquisition of its first U.S. facility—Syngene has gone from newcomer to a high-impact contributor within Greater Baltimore’s expanding biotech ecosystem. Their presence is helping grow advanced manufacturing capacity in the U.S., strengthen the local economy, and create new pathways for Maryland talent.
As 2026 approaches, one thing is clear: Syngene is firmly at home in Baltimore—and ready to start making medicines in Maryland.
